Loading
Latest filing published 31 Aug 2026 for 경동제약. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of 류 기 성 in 경동제약, where the filings describe the role as chief executive. In total, 29 filings cover trades dated from 19 February 2021 to 31 August 2026.
Both buying and selling appear: 26 purchases, against 1 sale. No amount is published for 27 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings 3 purchases and 1 sale.
None of the 25 purchases we analysed coincided with buying by another insider of the same company within 30 days.
The record was last updated on 31 August 2026 with a transaction in 경동제약. The most recent open-market purchase was published on 18 August 2026, 61 days ago. Filings reach the DART (FSS) feed a median of 42 days after the trade. Until a filing is published, the market cannot know about the trade. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 29 declarations